Serenity Medical Reports Long-Term River Stent Success in IIH
Maple Grove, Minn., July 22, 2026 Serenity Medical announced new four- to five-year clinical data demonstrating the long-term effectiveness...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
Maple Grove, Minn., July 22, 2026 Serenity Medical announced new four- to five-year clinical data demonstrating the long-term effectiveness...
HARRISON, N.Y., June 30, 2026 Serenity Medical announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough...
